🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Split 2:1 del 22/11/1999

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.656.089

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
16/11/2022 1,9400 USD
17/08/2022 1,9400 USD
16/05/2022 1,9400 USD
14/02/2022 1,9400 USD
15/11/2021 1,7600 USD
16/08/2021 1,7600 USD
14/05/2021 1,7600 USD
11/02/2021 1,7600 USD
13/11/2020 1,6000 USD
14/08/2020 1,6000 USD
15/05/2020 1,6000 USD
13/02/2020 1,6000 USD
14/11/2019 1,4500 USD
14/08/2019 1,4500 USD
16/05/2019 1,4500 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/03/2013 91,65 92,29 91,15 92,18 +0,70% 1,24% 3.436.800
13/03/2013 91,60 91,79 90,67 91,54 -0,23% 1,22% 2.606.100
12/03/2013 91,58 91,81 91,04 91,75 +0,34% 0,84% 4.997.500
11/03/2013 92,66 93,36 90,87 91,44 -1,68% 2,69% 5.699.600
08/03/2013 93,43 93,88 92,85 93,00 +0,05% 1,10% 3.084.900
07/03/2013 93,43 93,88 92,82 92,95 -0,34% 1,13% 2.980.100
06/03/2013 93,82 94,29 93,09 93,27 -0,18% 1,28% 3.716.300
05/03/2013 93,11 93,76 92,56 93,44 +0,77% 1,29% 3.570.200
04/03/2013 92,11 92,75 91,50 92,73 +0,16% 1,36% 3.186.700
01/03/2013 91,16 92,76 90,51 92,58 +1,13% 2,47% 4.317.700
28/02/2013 91,00 93,42 90,87 91,55 +0,57% 2,80% 6.528.600
27/02/2013 89,15 91,30 89,06 91,03 +1,74% 2,51% 3.549.800
26/02/2013 89,63 90,21 88,66 89,47 -0,09% 1,73% 4.805.200
25/02/2013 89,30 91,25 89,30 89,55 +3,14% 2,18% 11.422.400
22/02/2013 85,07 86,88 85,07 86,82 +1,99% 2,13% 4.920.400
21/02/2013 84,59 85,32 84,15 85,13 +0,57% 1,38% 4.094.200
20/02/2013 84,37 85,34 84,24 84,65 +0,62% 1,30% 6.388.300
19/02/2013 83,51 84,27 82,92 84,13 +0,62% 1,62% 5.944.300
15/02/2013 84,24 84,72 83,32 83,61 -1,31% 1,66% 5.622.200
14/02/2013 86,00 86,40 84,61 84,72 -0,26% 2,08% 6.189.100
13/02/2013 84,96 85,13 84,45 84,94 +0,47% 0,80% 7.943.200
12/02/2013 85,00 85,23 84,28 84,54 -0,45% 1,12% 4.656.000
11/02/2013 85,48 85,98 84,59 84,92 -2,13% 1,63% 7.538.400
08/02/2013 85,61 87,17 85,39 86,77 +1,82% 2,08% 8.354.900
07/02/2013 87,00 87,00 85,04 85,22 -1,58% 2,25% 7.639.700
06/02/2013 86,46 87,47 86,00 86,59 +0,07% 1,70% 5.549.100
05/02/2013 86,08 86,59 85,42 86,53 +0,92% 1,36% 4.577.900
04/02/2013 85,44 86,24 85,44 85,74 -0,65% 0,94% 3.907.500
01/02/2013 86,17 86,93 85,25 86,30 +0,98% 1,95% 3.379.500
31/01/2013 85,09 86,12 85,04 85,46 +0,09% 1,27% 4.269.700